Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. The company was founded in 1987 and is headquartered in New York, New York.

Delcath Systems Inc.

In a report released today, Swayampakula Ramakanth from H.C. Wainwright reiterated a Buy rating on Delcath Systems, with a price target of $30.00. ...

H.C. Wainwright Sticks to Its Buy Rating for Delcath Systems (DCTH)

The latest announcement is out from Delcath Systems ( ($DCTH) ). At its annual meeting of stockholders on May 13, 2026, Delcath Systems’ shareholde...

	A	B	C	D
1	Symbol	Price	Change	Volume
2	DCTH	$10.91	+0.74%	586.94K
3
4
5

	A	B	C	D
1	Symbol	Price	Change	Vol
2	DCTH	$10.91	+0.7%	586.94K
3
4
5
6

DCTH

DCTH

No Data Available

Get Delcath Systems Inc. Data in Excel

Get Delcath Systems Inc. Data in Excel